Wall, Donna

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersCRISPR and Genetic Engineering

Cited by 1,962

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., et al. (2024) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersVirus-based gene therapy research

Cited by 493

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersVirus-based gene therapy research

Cited by 253

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Frangoul, H., Bobruff, Y., Cappellini, M. D., Corbacioglu, S., Fernandez, C. M., de la Fuente, J., Grupp, S. A., Handgretinger, R., Ho, T. W., Imren, S., et al. (2020) · Blood

Hemoglobinopathies and Related DisordersVirus-based gene therapy research

Cited by 54

A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies

Ivison, S., Malek, M., Garcia, R. V., Broady, R., Halpin, A., Richaud, M., Brant, R. F., Wang, S.-I., Goupil, M., Guan, Q., et al. (2018) · JCI Insight

Clinical Laboratory Practices and Quality ControlT-cell and B-cell Immunology

Cited by 49